Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer

This study has been completed.
Information provided by (Responsible Party):
Cellectar Biosciences, Inc. Identifier:
First received: June 29, 2006
Last updated: November 7, 2011
Last verified: March 2010

The purpose of this clinical trial is to find out whether or not the combination of NOV-002 with chemotherapy (paclitaxel and carboplatin) is better at improving overall survival time when compared to chemotherapy alone in people with non-small cell lung cancer (NSCLC).

Earlier clinical trials in NSCLC showed that patients treated with NOV-002 in combination with chemotherapy had a better response (their tumors got smaller in one United States Phase 1/2 trial) than patients who received chemotherapy alone; and in two Phase 2 trials done in Russian patients, at the end of one year, patients treated with NOV-002 with chemotherapy had a better survival rate than patients who did not receive NOV-002 with their chemotherapy.

Condition Intervention Phase
Non Small Cell Lung Cancer
Drug: Paclitaxel and Carboplatin
Drug: NOV-002 Injection in combination with Carboplatin vs. Paclitaxel and Carboplatin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 3 Trial, Randomized, Open-Label, of NOV-002 in Combination With Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)

Resource links provided by NLM:

Further study details as provided by Cellectar Biosciences, Inc.:

Primary Outcome Measures:
  • Overall survival during the length of the trial, length of the trial is approximately two years after last patient in [ Time Frame: 16 months ]

Secondary Outcome Measures:
  • Improved progression-free survival (PFS) [ Time Frame: 16 months ]
  • Higher anti-tumor overall response rate (ORR) [ Time Frame: 16 months ]
  • Less myelosuppression and improved recovery from chemotherapy-induced myelosuppression [ Time Frame: 16 months ]
  • Immunomodulation as evidenced by changes in lymphocyte subsets [ Time Frame: 16 months ]

Estimated Enrollment: 880
Study Start Date: November 2006
Study Completion Date: February 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
NOV-002 Injection in combination with Carboplatin and Paclitaxel
Drug: NOV-002 Injection in combination with Carboplatin vs. Paclitaxel and Carboplatin

NOV-002: (Group A only)

  • Two 60mg intravenous boli given 3 hours apart administered the day prior to the first administration of paclitaxel and carboplatin cycle one
  • For each nominal 21-day paclitaxel and carboplatin cycle:

    • 60mg given intravenously on Day 1, given one hour prior to paclitaxel and carboplatin
    • followed by 60mg subcutaneously daily for the next 20 days. If there is a delay in chemotherapy cycles, the patient will continue with daily, subcutaneous administration of NOV-002 until the next cycle of chemotherapy begins.

Patients randomized to NOV-002 Group A, will receive NOV-002 until disease progression, unacceptable NOV-002 related toxicity, or discontinuation of paclitaxel and carboplatin, whichever comes first.

Other Name: NOV-002 Injection
Active Comparator: B
Paclitaxel and Carboplatin Alone
Drug: Paclitaxel and Carboplatin

Paclitaxel and carboplatin: (All randomized patients)

All randomized patients will follow the established 21-day cycle of paclitaxel and carboplatin including the administration of pre-medications for these products per the package inserts. Paclitaxel and carboplatin cycles will be administered until documented disease progression or completion of 6 cycles of paclitaxel and carboplatin in the absence of response or unacceptable related toxicity, whichever comes first.

The initial dose of chemotherapy for every patient in the trial is 200 mg/m2 of paclitaxel,as a 3 hour infusion, followed by carboplatin at an area under the curve (AUC) of 6 mg/mL/min using the Calvert equation for carboplatin dosing.

Detailed Description:

NSCLC is a widespread disease with extremely high mortality and morbidity. Even the most widely accepted standard of care chemotherapy in advanced NSCLC, platinum-based doublets, are only palliative, providing marginal efficacy as measured by survival. In addition, such chemotherapy is accompanied by severe, sometimes life-threatening, toxicities which often limit its application. Thus, there is a clear need for new, more effective and safer therapies for advanced NSCLC. In Phase 2 trials, NOV-002 demonstrated a higher response rate and improved survival compared to chemotherapy alone in patients with advanced NSCLC, and was well-tolerated in this patient group. Thus, we are conducting a large Phase 3 trial of NOV-002 to better define its clinical profile and potential benefit in advanced NSCLC patients.

The overall design of this Phase 3 trial reflects major elements of the previous Russian and US clinical trials in advanced NSCLC - it is an open label, randomized controlled trial comparing NOV-002 in combination with first-line chemotherapy (paclitaxel + carboplatin) to first-line chemotherapy alone. Furthermore, it is designed and powered to be a pivotal, registrational trial, sufficient for approval. As its primary efficacy endpoint, this Phase 3 trial aims to demonstrate that the combination of NOV-002 with paclitaxel and carboplatin results in improved overall survival when compared with paclitaxel and carboplatin alone. In addition, several secondary efficacy endpoints will be assessed, including progression free survival, tumor response rate and duration of response, quality of life, myelosuppression and immunomodulation. Overall survival was chosen as the primary endpoint of this trial in the context of FDA (Draft) Guidance ("Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics", April 2005). This Guidance indicates that an improvement in overall survival should be evaluated in randomized controlled trials and is of unquestioned clinical benefit. It indicates that the endpoint is precise and easy to measure, documented by the date of death, and states that bias is not a factor in endpoint measurement, and blinding is not essential. This Phase 3 randomized, controlled, open-label trial thus conforms to this Guidance.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of Stage IIIb with malignant pleural or pericardial effusion or Stage IV (American Joint Committee on Cancer [AJCC]) NSCLC
  • ECOG performance score of 0 or 1
  • Adequate bone marrow, hepatic, and renal function
  • New York Heart Association (NYHA) score 1-2
  • Life expectancy of at least 12 weeks
  • Women of child-bearing potential and men whose partners are of child-bearing potential must be willing to use an acceptable method of birth control during trial participation or are surgically sterile or women who are post-menopausal (defined as not having a menstrual cycle for greater than two years).
  • The patient or patient's legal representative has the ability to understand the requirements of the trial, has provided written informed consent, and agrees to abide by the trial restrictions and to return for the required assessments.
  • The patient must be able to self administer daily subcutaneous injections or his/her caregiver must be able to administer daily subcutaneous injections.

Exclusion Criteria:

  • Prior chemotherapy for advanced NSCLC or the patient has received prior neoadjuvant or adjuvant chemotherapy for NSCLC in the year prior to the date of randomization
  • Patients with central nervous system (CNS) metastases
  • Any systemic disease precluding chemotherapy
  • Chronic use of systemic corticosteroids in pharmacological doses
  • Known or history of HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
  • Contraindication to treatment with paclitaxel or carboplatin or any of the components of NOV-002
  • Any known preexisting medical condition, including substance abuse, that could interfere with the patient's participation in and completion of the protocol
  • Have received any investigational drug, defined as a drug for which there is no Food and Drug Administration (FDA) approved indication, within the 30 days prior to randomization
  • Pregnant female or nursing mother
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00347412

  Show 75 Study Locations
Sponsors and Collaborators
Cellectar Biosciences, Inc.
Study Chair: Thomas Lynch, MD Massachusetts General Hospital
Study Chair: Panos Fidias, MD Massachusetts General Hospital
  More Information

Responsible Party: Cellectar Biosciences, Inc. Identifier: NCT00347412     History of Changes
Other Study ID Numbers: NOV002-C301
Study First Received: June 29, 2006
Last Updated: November 7, 2011

Keywords provided by Cellectar Biosciences, Inc.:
Stage IIIb
Stage IV
Non Small Cell Lung Cancer (NSCLC)
NSCLC Stage IIIb with malignant pleural/pericardial effusion

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on April 28, 2017